Carret Asset Management LLC Has $4.89 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Carret Asset Management LLC raised its position in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 1.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 67,943 shares of the biopharmaceutical company’s stock after purchasing an additional 975 shares during the period. Carret Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $4,888,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. American National Bank lifted its holdings in Bristol-Myers Squibb by 19.5% in the fourth quarter. American National Bank now owns 4,764 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 777 shares during the period. Apella Capital LLC raised its position in shares of Bristol-Myers Squibb by 44.0% in the 4th quarter. Apella Capital LLC now owns 7,500 shares of the biopharmaceutical company’s stock worth $540,000 after acquiring an additional 2,292 shares in the last quarter. Gries Financial LLC lifted its stake in shares of Bristol-Myers Squibb by 23.9% in the 4th quarter. Gries Financial LLC now owns 46,236 shares of the biopharmaceutical company’s stock valued at $3,327,000 after purchasing an additional 8,911 shares during the period. Coldstream Capital Management Inc. bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $2,068,000. Finally, Bank of New Hampshire grew its stake in Bristol-Myers Squibb by 3.9% during the fourth quarter. Bank of New Hampshire now owns 23,641 shares of the biopharmaceutical company’s stock worth $1,701,000 after purchasing an additional 892 shares during the period. 75.51% of the stock is owned by institutional investors.

Bristol-Myers Squibb Trading Down 0.8 %

NYSE:BMY opened at $66.53 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.25 and a quick ratio of 1.14. The firm has a 50-day moving average of $70.96 and a 200-day moving average of $72.88. The company has a market cap of $139.63 billion, a PE ratio of 22.55, a PEG ratio of 1.44 and a beta of 0.46. Bristol-Myers Squibb has a one year low of $65.28 and a one year high of $81.43.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last posted its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the consensus estimate of $1.71 by $0.11. The company had revenue of $11.41 billion during the quarter, compared to the consensus estimate of $11.20 billion. Bristol-Myers Squibb had a net margin of 13.71% and a return on equity of 51.60%. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.83 earnings per share. As a group, equities research analysts expect that Bristol-Myers Squibb will post 8.07 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, May 1st. Investors of record on Monday, April 10th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 3.43%. The ex-dividend date is Thursday, April 6th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 77.29%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BMY. Morgan Stanley boosted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “underweight” rating in a research note on Friday, February 3rd. StockNews.com initiated coverage on shares of Bristol-Myers Squibb in a research note on Thursday. They set a “strong-buy” rating on the stock. Jefferies Financial Group began coverage on shares of Bristol-Myers Squibb in a report on Monday, March 6th. They issued a “hold” rating and a $62.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Bristol-Myers Squibb in a report on Tuesday, January 17th. They set an “overweight” rating and a $95.00 price objective on the stock. Finally, Atlantic Securities raised their target price on Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, February 3rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $79.69.

Insider Buying and Selling

In related news, EVP Ann Powell sold 11,183 shares of the business’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.69, for a total transaction of $835,258.27. Following the transaction, the executive vice president now directly owns 23,043 shares in the company, valued at $1,721,081.67. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 240,000 shares of the business’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.65, for a total value of $17,916,000.00. Following the transaction, the chief executive officer now directly owns 236,104 shares in the company, valued at $17,625,163.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Ann Powell sold 11,183 shares of the business’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.69, for a total transaction of $835,258.27. Following the completion of the transaction, the executive vice president now owns 23,043 shares in the company, valued at $1,721,081.67. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Company Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.